Drug | Page 241 of 280 | SpiritIndia.com

Smoking :: Nabi biopharmaceuticals completes enrollment in nicvax phase iib ‘proof-of-concept’ clinical trial

Nabi Biopharmaceuticals (Nasdaq: NABI) today announced it has completed enrollment for its Phase IIB “proof-of-concept” study for NicVAX(R) (Nicotine Conjugate Vaccine), the company’s novel, innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Enrollment for the trial was completed three months earlier than anticipated, paving the way for the release of trial results early in the second quarter of 2007.

Brain Cancer :: Peregrine receives regulatory approval for Cotara brain cancer clinical trial

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of cancer and hepatitis C virus infection, today announced that it has received regulatory approval in India for a new clinical trial of its lead tumor necrosis therapy (TNT) agent Cotara(R). The trial is designed to test the safety and efficacy of Cotara in patients with glioblastoma multiforme, a deadly form of brain cancer. Cotara is currently being studied in a multi-center U.S. glioblastoma trial. Previous studies using Cotara to treat brain cancer have produced encouraging results, and Peregrine expects that positive data from this trial in combination with data from the ongoing U.S. clinical trial should provide the foundation for planning the future development and commercialization of Cotara.

Pregnancy :: Next-generation contraceptive patch by Agile Therapeutics

Agile Therapeutics, a pharmaceutical development company focused on innovative transdermal products, is developing the next generation of contraceptive patches, one that is designed to deliver low doses of birth control hormones over a seven-day period.

Health :: New research to cut animal testing, uk

Researchers at The University of Manchester have been awarded 130,000 pounds to develop new techniques to reduce the need for animals in drug testing. Current checks to establish whether a new drug is carcinogenic can be inconclusive and require further testing on live animals to establish whether they are harmful or not.

Anger :: Intermittent Explosive Disorder (IED)

IED is defined as repeated and uncontrollable anger attacks that often become violent. IED is different from common type of anger most people exhibit from time to time when they pout, throw a book down or walk out of the room banging door, activities that are better described as mild temper tantrums.

Chikungunya :: Treating chikungunya with Ayurveda, Siddha

While the Allopathic system seems to have no medicine or treatment to cure or prevent the disease, or take care of the after-effects – most importantly severe joint pains – Ayurveda / Siddha Physicians have been routinely treating this fever.

Chikungunya :: What can people do to prevent becoming infected with chikungunya virus?

The best way to avoid CHIKV infection is to prevent mosquito bites. There is no vaccine or preventive drug. Prevention tips are similar to those for dengue or West Nile virus:

Smoking :: Naltrexone helps women to give up smoking

Adding the opiate blocker naltrexone to the combination of behavioral therapy and nicotine patches boosted smoking cessation rates for women by almost 50 percent when assessed after eight weeks of treatment, but made no difference for men, report researchers from the University of Chicago in the October 2006 issue of the journal Nicotine and Tobacco Research.

Autism :: Risperdal for treatment of irritability associated with autistic disorder

The U.S. Food and Drug Administration (FDA) approved a new use of one of the leading prescription antipsychotic medications, RISPERDAL(R) (risperidone), for the treatment of irritability associated with autistic disorder, including symptoms of aggression, deliberate self-injury, temper tantrums, and quickly changing moods, in children and adolescents aged 5 to 16 years.(1) This is the first time the FDA has approved any medication for use in children and adolescents with autism.

ADHD :: NRP104 (lisdexamfetamine dimesylate) for the treatment of adhd

Shire plc announced that its collaborative partner New River Pharmaceuticals Inc. (Nasdaq: NRPH) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD).